2012
DOI: 10.1111/j.1423-0410.2012.01632.x
|View full text |Cite
|
Sign up to set email alerts
|

Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G‐CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5‐year follow‐up study

Abstract: Background and Objectives  G‐CSF‐mobilized peripheral blood stem cells have long replaced marrow as the major source for allogeneic transplants. Conclusive evidence questioning the long‐term safety of G‐CSF for donors has not been provided, but the cumulative number of followed donors remains insufficient to rule out rare adverse events. A long‐term active follow‐up study of G‐CSF‐mobilized healthy volunteer donors was therefore performed. Patients and Methods  Two hundred and three successive donors were eval… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
55
0
2

Year Published

2013
2013
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 48 publications
(61 citation statements)
references
References 45 publications
4
55
0
2
Order By: Relevance
“…40 The EBMT conducted two survey-based studies to investigate the rate of events in both related and unrelated donors. 17 The first Only one case was in an unrelated donor (AML), while the remainder were in siblings.…”
Section: Incidence Of Haematological Malignancies In Healthy Donorsmentioning
confidence: 99%
“…40 The EBMT conducted two survey-based studies to investigate the rate of events in both related and unrelated donors. 17 The first Only one case was in an unrelated donor (AML), while the remainder were in siblings.…”
Section: Incidence Of Haematological Malignancies In Healthy Donorsmentioning
confidence: 99%
“…28 Adverse events associated with clinical use of G-CSF are not troublesome and seldom necessitate stopping therapy. 29 Mozobil is a more potent stem cell mobilizer than G-CSF 30 ; however, it is clinically approved only for acute and not chronic use. Both, Mozobil and G-CSF should be tested as it remains unclear whether Mozobilinduced substantial and short-term increase in circulating EPCs or moderate and long-term increase in EPC availability supported by G-CSF may be needed to advance atherosclerosis regression…”
Section: Epcs To Treat Atherosclerosis?mentioning
confidence: 99%
“…[49][50] However, three small studies of normal adult PBSC donors did not show clinically significant changes in white cell numbers and no donor leukemia was noted. [51][52][53] In a recent analysis, 203 healthy volunteer donors were followed up actively for 5 years after G-CSF-mobilized PBSCs were collected. 54 At the first follow-up of 4 weeks, all clinical and laboratory parameters had normalized to premobilization work-up levels.…”
Section: Donor Safetymentioning
confidence: 99%